Orally administered recombinant Lactobacillus casei vector vaccine expressing β-toxoid of Clostridium perfringens that induced protective immunity responses

Alimolaei, Mojtaba; Golchin, Mehdi; Ezatkhah, Majid

doi:10.1016/j.rvsc.2017.06.018

Cited by 14 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, antibiotic resistance genes such as erythromycin, kanamycin, and chloramphenicol are often used as markers to screen for genetically engineered LAB [26,33,41,42]. Although the use of antibiotic resistance as a screening marker is convenient for screening recombinant lactobacilli, there are potential biosafety risks with the application of antibiotic-resistant recombinant strains in practice, such as the dissemination of antibiotic resistance genes.…”

Section: Discussionmentioning

confidence: 99%

An EGFP-marked recombinant lactobacillus oral tetravalent vaccine constitutively expressing α, ε, β1, and β2 toxoids for Clostridium perfringens elicits effective anti-toxins protective immunity

et al. 2019

View full text Add to dashboard Cite

Clostridium perfringens is a common opportunistic pathogen endangering livestock and poultry breeds. Here, using enhanced green fluorescent protein as screening marker, a recombinant lactobacillus tetravalent vaccine constitutively expressing α, ϵ, β1, and β2 toxoids of C. perfringens was developed, and its immunogenicity in mice was investigated via oral administration. This probiotic vaccine could effectively induce antigen-specific secretory IgA (sIgA)-based mucosal and IgG-based humoral immune responses, and significantly high levels (p< 0.05) of cytokines IL-2, IL-4, IL-10, IL-12, IL-17, and IFN-γ were produced in immunized mice. Moreover, lymphoproliferation and percentage of CD4+ and CD8+ T cells significantly increased in mice of the probiotic vaccine group. Challenge experiments were performed in mice with C. perfringens toxinotypes A, C, and D crude toxins to evaluate protection efficiency of the probiotic vaccine, using a commercial inactivated C. perfringens vaccine made by C. perfringens toxinotypes A, C, and D as vaccine control. We observed 80% protection rate in the probiotic vaccine group, which was higher than commercial vaccine group, whereas all mice in control groups died and obvious histopathological changes were observed in liver, spleen, kidney, and intestines of mice. Significantly, we compared the immunogenicity and protection efficiency of lactobacillus constitutive expression system and lactobacillus inducible expression system, and results showed that lactobacillus constitutive expression system has obvious advantages. Our study clearly demonstrated that the probiotics vaccine could effectively induce mucosal, humoral, and cellular immunity, and provide effective protection against C. perfringens toxins, suggesting a promising strategy for the development of oral vaccine against C. perfringens.

show abstract

Section: Discussionmentioning

confidence: 99%

An EGFP-marked recombinant lactobacillus oral tetravalent vaccine constitutively expressing α, ε, β1, and β2 toxoids for Clostridium perfringens elicits effective anti-toxins protective immunity

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Leukocyte phagocytic function was slightly modified as follows: after blood collection, 200 µL of blood from each fish group was dropped into heparinized centrifuge tubes, to which 100 µL bacterial suspension of Staphylococcus aureus was added before shaking, according to Avtalion et al [47]. The tubes were kept at 28 • C in a water bath for 30 min, and shaken every 10 min in order to centrifuge as recommended by Cai et al [48]. The supernatant was discarded, and the upper layer of the precipitate was used to make blood slides.…”

Section: Phagocytic Activity Of Leukocytementioning

confidence: 99%

Oral Administration of Lactobacillus Casei Expressing Flagellin A Protein Confers Effective Protection against Aeromonas Veronii in Common Carp, Cyprinus Carpio

Tian

Kang

Chu

et al. 2019

IJMS

View full text Add to dashboard Cite

Aeromonas veronii is a pathogen capable of infecting humans, livestock and aquatic animals, resulting in serious economic losses. In this study, two recombinant Lactobacillus casei expressing flagellin A (FlaA) of A. veronii, Lc-pPG-1-FlaA (surface-displayed) and Lc-pPG-2-FlaA (secretory) were constructed. The immune responses in fish administered with recombinant L. casei were evaluated. The two recombinant L. casei were orally administered to common carp, which stimulated high serum IgM and induced higher ACP, AKP, SOD and LYZ activity. Using qRT-PCR, the expression of IL-10, IL-8, IL-1β, TNF-α and IFN-γ in the tissue of fish immunized with recombinant L. casei was significantly (p < 0.05) upregulated, which indicated that recombinant L. casei could activate the innate immune system to trigger the cell immune response and inflammatory response. Furthermore, recombinant L. casei was able to survive the intestinal environment and colonize in intestine mucosal. The study showed that after being challenged by A. veronii, fish administered with Lc-pPG-1-FlaA (70%) and Lc-pPG-2-FlaA (50%) had higher survival rates compared to Lc-pPG and PBS, indicating that recombinant L. casei might prevent A. veronii infection by activating the immune system to trigger immune responses. We demonstrated that flagellin as an antigen of vaccine, is acceptable for preventing A. veronii infection in fish. The recombinant L. casei expressing FlaA may be a novel mucosal vaccine for treating and controlling A. veronii.

show abstract

“…The bacteria is also considered an attractive candidates as live carriers for the delivery of antigens to the intestinal mucosa due to the ability of potent survival in the digestive tract, close association with the intestinal epithelium and immunomodulatory properties (Wells & Mercenier, ; Yu, Zhu, Kang, & Yang, ). The oral or intranasal administration of vaccines based on Lactobacillus is a promising strategy to elicit strong humoural and cellular immune responses both in the systemic and the mucosal sites (Alimolaei, Golchin, & Ezatkhah, ; Stoeker et al., ). The injection of L. casei Shirota strain (LcS) in CD1 mice showed an increase in anti‐ T. spiralis IgA production with the decrease in adult worm loadings (Martínez‐Gómez, Santiago‐Rosales, & Ramón Bautista‐Garfias, ).…”

Section: Challenges and Opportunitiesmentioning

confidence: 99%

Vaccines againstTrichinella spiralis: Progress, challenges and future prospects

Zhang

2018

Transbound Emerg Dis

View full text Add to dashboard Cite

Trichinella spiralis, the causative agent of trichinellosis, is able to infect a wide range of carnivores and omnivores including human beings. In the past 30 years, a mass of vaccination efforts has been performed to control T. spiralis infection with the purpose of reduction in worm fecundity or decrease in muscle larval and adult burdens. Here, we summarize the development of veterinary vaccines against T. spiralis infection. During recent years, increasing numbers of new vaccine candidates have been developed on the protective immunity against T. spiralis infection in murine model. The vaccine candidates were not only selected from excretory-secretory (ES) antigens, but also from the recombinant functional proteins, such as proteases and some other antigens participated in T. spiralis intracellular processes. However, immunization with a single antigen generally revealed lower protective effects against T. spiralis infection in mice compared to that with the inactivated whole worms or crude extraction and ES productions. Future study of T. spiralis vaccines should focus on evaluation of the protective efficacy of antigens and/or ligands delivered by nanoparticles that could elicit Th2-type immune response on experimental pigs.

show abstract

Orally administered recombinant Lactobacillus casei vector vaccine expressing β-toxoid of Clostridium perfringens that induced protective immunity responses

Cited by 14 publications

References 37 publications

An EGFP-marked recombinant lactobacillus oral tetravalent vaccine constitutively expressing α, ε, β1, and β2 toxoids for Clostridium perfringens elicits effective anti-toxins protective immunity

An EGFP-marked recombinant lactobacillus oral tetravalent vaccine constitutively expressing α, ε, β1, and β2 toxoids for Clostridium perfringens elicits effective anti-toxins protective immunity

Oral Administration of Lactobacillus Casei Expressing Flagellin A Protein Confers Effective Protection against Aeromonas Veronii in Common Carp, Cyprinus Carpio

Vaccines againstTrichinella spiralis: Progress, challenges and future prospects

Contact Info

Product

Resources

About